PHOX2B and neuroblastoma: MRD detection in BM samples evaluated by a set of five markers (CHRNA3, DDC, GAP43, PHOX2B, and TH) was associated with poor outcome in patients aged over 1 year with stage 4 neuroblastoma (96).